The Medical Advisor

Introduction Milk has long been promoted as a nutrient-rich staple for bone health and overall wellness. However,  claims—such as those from NOVOS Labs —suggest that milk may actually accelerate aging by activating pathways like IGF-1 and mTOR. But how strong is this claim? In this evidence-based review, we separate biological theory from real-world human data, and examine whether milk truly impacts aging—or if the concern is overstated. The Biological Argument: Why Milk Could Influence Aging Milk contains bioactive compounds that can influence key aging-related pathways: 1. IGF-1 (Insulin-Like Growth Factor 1) Milk consumption is associated with modest increases in IGF-1 IGF-1 promotes: Growth and repair Cell proliferation 👉 In animal models, chronically high IGF-1 is linked to shorter lifespan 2. mTOR Activation Milk proteins (especially whey) activate mTOR (mechanistic target of rapamycin) mTOR regulates: Protein synthesis Cell growth 👉 Overactivation of mTOR is associated w...

Milk can accelerate aging in various ways. Given milk impacts aging, which is a process that by definition takes a long time, it takes decades for these effects to manifest. However, milk can even have immediate pro-aging effects, like increasing insulin resistance or increasing the production of insulin drastically, as we will discuss below. In this article, we will explain several mechanisms by which milk can accelerate aging. How milk stimulates pro-aging growth pathways Milk is made by nature to make calves grow quickly. That’s why milk contains many substances to stimulate growth. However, growth stimulation also accelerates aging. One red thread through all aging research (biogerontology) is that too much stimulation of growth leads to faster aging. More precisely, milk contains various substances that stimulate growth receptors in cells, like insulin receptors, mTOR receptors, and insulin-like growth factor (IGF) receptors, making cells age faster. In biogerontology (the scienc...

Introduction In an era where conventional cancer treatments often come with significant side effects and variable success rates, alternative therapies are gaining attention for their potential accessibility and lower toxicity. This exploration delves into the emerging use of topical ivermectin—a well-established antiparasitic medication—for treating skin cancers such as basal cell carcinoma, squamous cell carcinoma, and melanoma. Drawing from a compilation of anecdotal success stories, case reports, and preliminary scientific insights, we examine how this affordable, over-the-counter option might disrupt traditional dermatological approaches. While not a substitute for professional medical advice, these narratives highlight patient-driven innovations that challenge the status quo, prompting a closer look at ivermectin's multifaceted mechanisms and real-world applications. Case Presentations Case 16 - 2026: 66 year old Texas nurse with Basal Cell Carcinoma at the nose/cheek jun...